Denali Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Denali Therapeutics

23/02/2024 11:08

* Denali Therapeutics Inc  DNLI.OQ   DNLI.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
26 (estimated) for the period ending December 31 2023
    * The South San Francisco California-based  company is
expected to
report a 18.7% decrease in revenue to $8.365 million from $10.28
million a year ago, according to the mean estimate from 14
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Denali Therapeutics Inc
is for
a loss of 80 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Denali
Therapeutics Inc is $39.00​, above​ its last closing price
of $16.83. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.78       -0.80      -0.72     Beat    10.3
 Jun. 30 2023  -0.60       -0.68      1.30      Beat    290.1
 Mar. 31 2023  -0.71       -0.70      -0.80     Missed  -13.6​
 Dec. 31 2022  -0.77       -0.79      -0.75     Beat    5.1
 ​​Sep.        -0.78       -0.81      -0.84     Missed  -4.2
 30 2022                                                
 Jun. 30 2022  -0.53       -0.55      -0.48     Beat    12.6​
 Mar. 31 2022  -0.51       -0.51      -0.53     Missed  -4.3
 Dec. 31 2021  -0.43       -0.41      -0.62     Missed  -49.8
 This summary was machine generated February 23 at 11:08 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)